Diabetes is a chronic metabolic disease that cause high blood sugar due to which body becomes incapable of producing insulin. According to World Health Organization (WHO), India had 69.2 million people living with diabetes (8.7%) in 2015. About 90% of the patients are suffering from Type 2 diabetes. Increasing awareness, increasing number of patients, untouched rural market, increasing urbanization, developing healthcare infrastructure and increasing spending on healthcare are driving the market for diabetes in India. India Diabetes Market is expected to grow at the average CAGR of 6.5% during 2016-2023. India Diabetes Market is growing rapidly. India Diabetes Market is expected to grow US$ 7441.6 million by 2023 from US$ 4778.7 million in 2016.
Segments:
India Diabetes Market has been segmented on the basis of type which comprise Type 1, Type 2, and Gestational diabetes. On the basis of test market is segmented into Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others. On the basis of devices, it is segmented into Blood glucose monitoring devices, Diabetes management devices, and others. On the basis of treatment, market is segmented into Medications, Insulin therapy, Transplantation, Bariatric surgery and others.
Key Players for India Diabetes Market:
Some of the key players in this market are: Novo Nordisk A/S (Denmark), USV Private Limited (India), sanofi-aventis U.S. LLC (US), Novartis AG (Switzerland), Merck & Co., Inc. (US), Becton Dickinson and Company (US), Roche Diabetes Care, Inc.(US),Johnson & Johnson Services, Inc.(us), Bayer AG (Germany), Ypsomed (Switzerland)
Request Customization
Get a Sample
Get a Sample
Request Customization